JP2021524453A5 - - Google Patents

Info

Publication number
JP2021524453A5
JP2021524453A5 JP2020564577A JP2020564577A JP2021524453A5 JP 2021524453 A5 JP2021524453 A5 JP 2021524453A5 JP 2020564577 A JP2020564577 A JP 2020564577A JP 2020564577 A JP2020564577 A JP 2020564577A JP 2021524453 A5 JP2021524453 A5 JP 2021524453A5
Authority
JP
Japan
Prior art keywords
compound
general formula
alkyl
groups
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020564577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524453A (ja
JP7333793B2 (ja
Filing date
Publication date
Priority claimed from GBGB1808093.7A external-priority patent/GB201808093D0/en
Application filed filed Critical
Publication of JP2021524453A publication Critical patent/JP2021524453A/ja
Publication of JP2021524453A5 publication Critical patent/JP2021524453A5/ja
Application granted granted Critical
Publication of JP7333793B2 publication Critical patent/JP7333793B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564577A 2018-05-18 2019-05-17 化合物 Active JP7333793B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1808093.7 2018-05-18
GBGB1808093.7A GB201808093D0 (en) 2018-05-18 2018-05-18 Compounds
PCT/GB2019/051383 WO2019220147A1 (en) 2018-05-18 2019-05-17 Compounds

Publications (3)

Publication Number Publication Date
JP2021524453A JP2021524453A (ja) 2021-09-13
JP2021524453A5 true JP2021524453A5 (cg-RX-API-DMAC7.html) 2022-05-09
JP7333793B2 JP7333793B2 (ja) 2023-08-25

Family

ID=62723333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564577A Active JP7333793B2 (ja) 2018-05-18 2019-05-17 化合物

Country Status (5)

Country Link
US (1) US12037336B2 (cg-RX-API-DMAC7.html)
EP (1) EP3794002B1 (cg-RX-API-DMAC7.html)
JP (1) JP7333793B2 (cg-RX-API-DMAC7.html)
GB (1) GB201808093D0 (cg-RX-API-DMAC7.html)
WO (1) WO2019220147A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220050126A (ko) 2019-06-12 2022-04-22 티엠이엠16에이 리미티드 호흡기 질환을 치료하기 위한 화합물
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
TW202237090A (zh) 2020-12-11 2022-10-01 英商Tmem16A有限公司 治療呼吸道疾病之化合物
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US11617716B2 (en) 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US12661315B2 (en) 2021-06-10 2026-06-23 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
WO2022266190A1 (en) 2021-06-16 2022-12-22 Blueprint Medicines Corporation Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors
CN117897384A (zh) 2021-06-28 2024-04-16 缆图药品公司 Cdk2抑制剂
CN117946013B (zh) * 2024-01-25 2024-07-02 白银康寓信生物科技有限公司 一锅法合成5,6-二卤代-3-氨基吡嗪-2-甲酸甲酯的方法
US20260108465A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
CA2534568A1 (en) 2003-08-18 2005-03-24 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers
EP1670474A4 (en) 2003-08-18 2008-08-06 Parion Sciences Inc CYCLIC PYRAZINOYLGUANIDINE AS SODIUM CHANNEL BLOCKER
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
AU2004266704B2 (en) 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US8288391B2 (en) 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
WO2009139948A1 (en) 2008-02-26 2009-11-19 Johnson Michael R Poly aromatic sodium channel blockers
MX2010012441A (es) 2008-05-13 2010-12-06 Novartis Ag Derivados de acido 3,5-diamino-6-cloro-pirazin-2-carboxilico y su uso como bloqueadores del canal de sodio epitelial para el tratamiento de enfermedades de las vias respiratorias.
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
NO2773633T3 (cg-RX-API-DMAC7.html) 2011-11-02 2017-12-30
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
WO2013181232A2 (en) 2012-05-29 2013-12-05 Michael Ross Johnson Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
WO2014044849A1 (en) 2012-09-24 2014-03-27 Boehringer Ingelheim International Gmbh Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
EP2991981B1 (en) 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
CA2915633A1 (en) 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
WO2015003958A1 (en) 2013-07-08 2015-01-15 Boehringer Ingelheim International Gmbh Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
WO2015007519A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel benzimidazolium compounds
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
WO2015007516A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel 5-substituted benzimidazolium compounds
EP3030555B1 (en) 2013-08-08 2019-01-30 Boehringer Ingelheim International GmbH Novel pyrazine amide compounds
US9932324B2 (en) 2015-01-12 2018-04-03 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
US10155749B2 (en) 2015-01-12 2018-12-18 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
EP3245200B1 (en) 2015-01-12 2021-03-10 Boehringer Ingelheim International GmbH 2-(pyrazin-2-ylcarbonylaminomethyl)benzimidazolium compounds as epithelial sodium channel inhibitors
EP3245202B1 (en) 2015-01-12 2020-03-11 Boehringer Ingelheim International GmbH Tetrasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases
MX2018002006A (es) 2015-08-20 2018-06-19 Boehringer Ingelheim Int Benzamidas apareadas novedosas.
EP3298022B1 (en) 2015-08-20 2019-06-05 Boehringer Ingelheim International GmbH Novel annelated phenoxyacetamides
GB201610854D0 (en) * 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Similar Documents

Publication Publication Date Title
JP2019535747A5 (cg-RX-API-DMAC7.html)
ES2315425T3 (es) Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos.
HRP20230294T1 (hr) Modulatori tmem16a
JP2013530179A5 (cg-RX-API-DMAC7.html)
JP2009535340A5 (cg-RX-API-DMAC7.html)
JP2013510883A5 (cg-RX-API-DMAC7.html)
JP2011162556A5 (cg-RX-API-DMAC7.html)
JP2007500187A5 (cg-RX-API-DMAC7.html)
JP2018529657A5 (cg-RX-API-DMAC7.html)
JP2020537658A5 (cg-RX-API-DMAC7.html)
AU2018303782A1 (en) New crystalline forms of vilanterol trifenatate and processes for their preparation
JP2009040767A5 (cg-RX-API-DMAC7.html)
US6946486B2 (en) Quaternary ammonium compounds
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
JP2016506946A (ja) 吸入療法用の多成分結晶粒子
JP2006506402A (ja) 四級アンモニウム化合物およびその抗ムスカリン薬としての使用
RU2015115677A (ru) Производные 6-аминоиндола в качестве антагонистов канала с транзиторным рецепторным потенциалом (trp)
US6878730B2 (en) Quaternary ammonium compounds
SK5262003A3 (en) Propellant-free liquid inhalation formulation containing a combination of at least two active substances, method for producing thereof and its use
NZ753048B2 (en) Benzodiazolium compounds as enac inhibitors
JP2006511494A (ja) 抗ムスカリン剤としてのキヌクリジニウム誘導体
NZ753048A (en) Benzodiazolium compounds as enac inhibitors
HRP20120678T1 (hr) Farmaceutski pripravci zasnovani na antagonistima kininskog b2 receptora i kortikosteroidima te njihova upotreba
JP2011527689A (ja) 2−[4−(4−フルオロ−ベンジル)−ピペリジン−1−イル]−2−オキソ−n−(2−オキソ−2,3−ジヒドロ−ベンゾオキサゾール−6−イル)−アセトアミドの結晶形態
ES2991169T3 (es) Formulación sólida de un derivado de 1,2,4-oxadiazol